In cancer patients, treatment with both anti-CTLA-4 and PD-1/PD-L1 inhibitors is associated with an increase in Th17 cells [103–105], so there is not enough evidence for the use of immune checkpoint inhibitors in sarcoidosis, particularly given the likely importance of Th17 cells in progression of sarcoidosis. This evidence concerns the gene CD274 and sarcoidosis.